Business
MetaStat Welcomes Renato T. Skerlj, Ph.D., Accomplished Drug Developer to Its Scientific and Clinical Advisory Board
MetaStat Welcomes Renato T. Skerlj, Ph.D., Accomplished Drug Developer to Its Scientific and Clinical Advisory Board.
About this update from Metastat Inc
[{"type":"text","content":"\n \n MetaStat, Inc. (OTCQB:MTST), a personalized medicine company \n developing therapeutic and diagnostic treatment solutions for cancer \n patients, announced today accomplished drug developer, Renato T. Skerlj, \n Ph.D., has joined the company as a member of its Scientific and Clinical \n Advisory Board.\n \n \n “MetaStat’s proprietary driver-based pan-cancer biomarkers are exciting \n targets for cancer drug development. They represent the promise of \n personalized medicine and the potential for new targeted cancer \n therapies that address major treatment challenges facing oncologists and \n their patients,” said Dr. Skerlj.\n \n \n “I am especially delighted to welcome Dr. Skerlj to MetaStat’s SAB to \n help with our internal anti-metastatic drug development program. \n Renato’s knowledge, experience and successful track record are \n invaluable assets to help us efficiently advance our small molecule \n program that is aimed at preventing aggressive cancer from spreading,” \n stated Douglas. A. Hamilton, MetaStat’s President and CEO.\n \n \n Dr. Skerlj serves as Vice President of Drug Discovery and Preclinical \n Development at Lysosomal Therapeutics Inc. Dr. Skerlj is a co-founder \n and a Member of Scientific Advisory Board of X4 Pharmaceuticals Inc. and \n co-founder of Noliva Therapeutics. He has over 25 years of \n pharmaceutical experience in drug development resulting in two marketed \n drugs: Invanz® and Mozobil® and multiple drugs in \n clinical development. Previously, Dr. Skerlj served as the Head of Small \n Molecule Discovery at Genzyme, prior to its acquisition by Sanofi. He \n served as Vice President of Chemistry for AnorMED Inc., a \n publicly-traded company acquired by Genzyme for $580 million in 2006. \n Prior to AnorMED Inc., Dr. Skerlj served as a Senior Research Chemist at \n Merck & Co., Inc. and Senior Scientist at Johnson Matthey's biomedical \n research group. Dr. Skerlj earned his doctorate from the University of \n British Columbia and completed a fellowship at the University of Oxford \n in Dr. Stephen Davies’ laboratory.\n \n \n About MetaStat, Inc.\n \n \n MetaStat is a biotechnology company focused on discovering and \n developing personalized therapeutic and diagnostic treatment solutions \n for cancer patients. Our...